Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia

Autor:	Anna-Maria Fink, Kirsten Fischer, Sandra Robrecht, Paula Cramer, Barbara Eichhorst, Petra Langerbeins, Anja Engelke, Stephan Stilgenbauer, Othman Al-Sawaf, Moritz Fürstenau, Michael Hallek, Jasmin Bahlo, Sebastian Boettcher, Von Tresckow Julia, Clemens M. Wendtner, Karl Anton Kreuzer, Matthias Ritgen
Rok vydání:	2018
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Chronic lymphocytic leukemia Ofatumumab medicine.disease chemistry.chemical_compound chemistry Obinutuzumab Internal medicine Ibrutinib medicine business
Zdroj:	Journal of Clinical Oncology. 36:7513-7513
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.7513
Popis:	7513Background: The German CLL study group (GCLLSG) performed three similar phase-II-trials combining a CD20-antibody, ofatumumab (O) or obinutuzumab (G, for GA-101), with ibrutinib (I) or venetocl...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ad4ef585009113b7fc49f63673c7d5b2 https://doi.org/10.1200/jco.2018.36.15_suppl.7513 Zobrazit plný text záznamu